glp 1 loss weight GLP-1 drugs leave users low on key nutrients, study finds Unlocking The Power of GLP-1

Farxiga/Forxiga is not currently approved for weight loss as a standalone indication in non-diabetics, but the evidence is accumulating: Currently, if weight loss is the primary goal in a non-diabetic patient, GLP-1 agonists (semaglutide/Ozempic, tirzepatide/Mounjaro) produce substantially greater weight loss (1015% vs 24%)

Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review

Self-injection considerations Patients using injectable formulations need to be comfortable with self-injection

They dont just lose fat

This approach assessed persistence versus switching among those active in both months, and therefore, did not evaluate discontinuation (no fill in the subsequent month)

In addition, 37.0% of people treated with 2.4 mg semaglutide achieved improvements in liver fibrosis with no worsening of steatohepatitis compared to 22.5% on placebo